



# 2021 Retinal Pharmaceuticals Market Report

Global Analysis for 2020 to 2026

**\$14.1B**

2021 MARKET  
FORECAST

**33**

COMPETITOR  
PROFILES

**331**

COMPREHENSIVE  
PAGES

**8**

GEOGRAPHIC AND  
ECONOMIC BREAKOUTS

# What's New

AUTHOR  
Peter Downs  
PUBLISHED  
August 2021

The “2021 Retinal Pharmaceuticals Market Report” features an updated disease prevalence model by ethnicity and now covers more development-stage categories, therapies, and companies. The report features new discussions of gene therapy delivery methods; DR, PDF, and NPDR treatment in the US; pharmaceutical treatment for vitreous hemorrhage; plans for Beovu use in the US; and potentially disruptive technologies. Sales forecasts through 2026 have been refreshed following the COVID-19 pandemic and also with an outlook for sustained drug delivery.

## Market Scope


# 2021 Retinal Pharmaceuticals Market Report

The “2021 Retinal Pharmaceuticals Market Report” analyzes the prevalence and treatment market of retinal diseases and discusses important trends and key factors for future market success. It examines the market’s evolution and forecasts growth over the next five years. Product demand is forecasted in units and dollars, and market shares are analyzed by product category. Our coverage includes:


- Discussions of retinal diseases and their risk factors.
- Diagnosis and treatment of these diseases.
- A global view of retinal care and retina specialists.
- Retinal pharmaceuticals and biologics in the marketplace.
- Investigational agents in the development pipeline.
- Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional companies with preclinical programs.

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, biosimilars, complement inhibitors expected to enter the marketplace within five years, gene therapies, and others. The report also includes a separate forecast for sustained drug-delivery devices in retina and also delves into the development pipelines of 11 categories of retinal pharmaceuticals.

**Retinal Pharmaceuticals Market Share in Revenue by Product**



**Global Prevalence of Retinal Diseases by Region in 2021**



In addition to profiles of 33 market competitors, the report also covers 161 companies that have retina pharmaceuticals and biologics in very early development; early-stage companies that have out-licensed retina drug candidates; and companies with drug delivery technologies in development that may be applicable to retina.

Market Scope designed this report to provide value to members of the ophthalmic industry who participate in the retinal pharmaceuticals market (or are weighing the option of doing so), market analysts, retina specialists, investors, and any other parties interested in the marketplace for these retinal treatments.

## How to Order


Order your “2021 Retinal Pharmaceuticals Market Report” now at [www.market-scope.com](http://www.market-scope.com) or contact us directly via email or phone.



### ENTERPRISE LICENSE

2021 Retinal Pharmaceuticals  
Market Report  
**\$11,625**

*(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)*



### SINGLE-USER LICENSE

2021 Retinal Pharmaceuticals  
Market Report  
**\$7,750**

Printed Copy      **\$250**



### ONE-YEAR SUBSCRIPTION

Ophthalmic Market  
Perspectives Newsletter  
**\$1,100**

International Shipping **\$50**

**314.835.0600** | [info@market-scope.com](mailto:info@market-scope.com)

## Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

